- Global Pharma News & Resources

Epigenomics AG: CMS accepts Epigenomics' application for NCD review

DGAP-News: Epigenomics AG / Key word(s): Regulatory Admission/Miscellaneous

03.05.2019 / 10:09
The issuer is solely responsible for the content of this announcement.

CMS accepts Epigenomics' application for NCD review

Berlin (Germany) and San Diego, CA (U.S.A.), May 2, 2019 - Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the "Company") announces that the Centers for Medicare & Medicaid Services (CMS) has accepted the company's application for a National Coverage Determination (NCD) review of Epi proColon, Epigenomics' blood test for colorectal cancer screening. The NCD is one of two options to obtain CMS coverage for Epi proColon, which would represent a major U.S. market breakthrough for the company. With this step, no decision has yet been made on coverage, but CMS has determined that there is a rationale to accept the NCD review at this time.

While CMS has accepted the application, due to the limitation of resources, CMS will not "Open" the NCD review process immediately. Once CMS resources are available the NCD will be "Opened", by initiating a 30-day public comment period and CMS will issue a proposed decision within six months per legal statute. If this proposed coverage decision is positive, another 30-day comment period follows. CMS will publish its final decision within 90 days of the initial proposed decision.

"The acceptance of our NCD application by CMS is a major step forward to achieve reimbursement as we will have a definitive answer within six to nine months of CMS opening the review period", said Greg Hamilton, CEO of Epigenomics AG. "Additionally, we will continue to pursue the legislative path for reimbursement as we believe this option is also a viable solution. Overall, we are optimistic that we will receive a coverage decision for Epi proColon."

About Epigenomics

Epigenomics is a molecular diagnostics company focused on blood-based detection of cancers using its proprietary DNA methylation biomarker technology. The company develops and commercializes diagnostic products across multiple cancer indications with high medical need. Epigenomics' lead product, Epi proColon(R), is a blood-based screening test for the detection of colorectal cancer. Epi proColon has received approval from the U.S. Food and Drug Administration (FDA) and is currently marketed in the United States, Europe, and China and selected other countries. Epi proLung(R), a blood-based test for lung cancer detection, and HCCBloodTest, a blood-based test for liver cancer detection in cirrohtic patients, have received CE mark in Europe.

For more information, visit


Epigenomics AG, Geneststrasse 5, 10829 Berlin, Tel +49 (0) 30 24345 0, Fax +49 (0) 30 24345 555, E-Mail:

Investor Relations
IR.on AG, Frederic Hilke, Tel +49 221 9140 970, E-Mail:

24345 386, Fax +49 (0) 30 24345 555, E-Mail:

Epigenomics legal disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any expected results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

03.05.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at

Language: English
Company: Epigenomics AG
Geneststra├če 5
10829 Berlin
Phone: +49 30 24345-0
Fax: +49 30 24345-555
ISIN: DE000A11QW50
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 806879

End of News DGAP News Service

Editor Details

Last Updated: 03-May-2019